

# Laurent Arthur DÃ©costerd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7104386/publications.pdf>

Version: 2024-02-01

264  
papers

11,025  
citations

44444

50  
h-index

48101

92  
g-index

273  
all docs

273  
docs citations

273  
times ranked

12436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 290-302.	1.3	47
2	Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2022, 94, 66-69.	0.9	4
3	HDLs extract lipophilic drugs from cells. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	2
4	Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac043.	0.9	5
5	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 458-470.	1.1	12
6	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 471-484.	2.3	10
7	No renal dysfunction or salt and water retention in acute mountain sickness at 4,559 m among young resting males after passive ascent. <i>Journal of Applied Physiology</i> , 2021, 130, 226-236.	1.2	9
8	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 379-390.	1.6	4
9	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 979-987.	0.8	2
10	Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1025-1029.	2.3	8
11	A Hyaluronic Acid Hydrogel Loaded with Gentamicin and Vancomycin Successfully Eradicates Chronic Methicillin-Resistant <i>Staphylococcus aureus</i> Orthopedic Infection in a Sheep Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	27
12	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	1.1	0
13	Seizure freedom and plasma levels of newer generation antiseizure medications. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 202-208.	1.0	8
14	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. <i>JMIR Research Protocols</i> , 2021, 10, e30090.	0.5	7
15	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, , .	1.3	2
16	Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID -imatinib study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1497-1511.	1.3	8
17	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. <i>EClinicalMedicine</i> , 2021, 42, 101188.	3.2	5
18	Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!. <i>Frontiers in Pediatrics</i> , 2021, 9, 768438.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Compassionate Use of Letemovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 96-99.	0.6	10
20	Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH. <i>Drug Metabolism Letters</i> , 2020, 13, 102-110.	0.5	9
21	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. <i>Annals of Neurology</i> , 2020, 87, 22-29.	2.8	30
22	The Neurocognitive Assessment in the Metabolic and Aging Cohort (<sc>NAMACO</sc>) study: baseline participant profile. <i>HIV Medicine</i> , 2020, 21, 30-42.	1.0	24
23	How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?. <i>HIV Medicine</i> , 2020, 21, 342-348.	1.0	14
24	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 33-44.	1.0	25
25	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	1.0	18
26	Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. <i>BMJ Open</i> , 2020, 10, e040110.	0.8	5
27	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. <i>Frontiers in Pharmacology</i> , 2020, 11, 177.	1.6	59
28	Validation and clinical application of a multiplex high performance liquid chromatography tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1157, 122160.	1.2	38
29	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bicitegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	0.7	22
30	Real-life management of drug-drug interactions between antiretrovirals and statins. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1972-1980.	1.3	8
31	Aging does not impact drug-drug interaction magnitudes with antiretrovirals. <i>Aids</i> , 2020, 34, 949-952.	1.0	2
32	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	1.6	5
33	Sultiam pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00558.	1.1	8
34	Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. <i>Nature Communications</i> , 2020, 11, 721.	5.8	38
35	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™ HIV trial. <i>PLoS Medicine</i> , 2020, 17, e1003421.	3.9	23
36	Title is missing!. , 2020, 17, e1003421.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 17, e1003421.		0
38	Title is missing!. , 2020, 17, e1003421.		0
39	Title is missing!. , 2020, 17, e1003421.		0
40	Title is missing!. , 2020, 17, e1003421.		0
41	Title is missing!. , 2020, 17, e1003421.		0
42	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121733.	1.2	10
43	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2690-2697.	1.3	23
44	Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. <i>PLoS ONE</i> , 2019, 14, e0217139.	1.1	14
45	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	1.1	7
46	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2468-2470.	1.3	3
47	Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. <i>Malaria Journal</i> , 2019, 18, 139.	0.8	10
48	Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1616-1618.	1.1	6
49	Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0210789.	1.1	3
50	Isavuconazole brain penetration in cerebral aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1751-1753.	1.3	30
51	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz531.	0.4	38
52	Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response. <i>Epilepsy Research</i> , 2019, 149, 88-91.	0.8	36
53	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1489-1497.	2.9	19
54	Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12

#	ARTICLE	IF	CITATIONS
55	LC-MS/MS method for the simultaneous analysis of seven antimalarials and two active metabolites in dried blood spots for applications in field trials: Analytical and clinical validation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 154, 263-277.	1.4	33
56	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 124-136.	1.2	31
57	The Antimalarial Drug Artesunate Attenuates Cardiac Injury in A Rodent Model of Myocardial Infarction. <i>Shock</i> , 2018, 49, 675-681.	1.0	17
58	Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. <i>Nature Communications</i> , 2018, 9, 4848.	5.8	29
59	In vitro study of new combinations for local antibiotic therapy with calcium sulphate - Near constant release of ceftriaxone offers new treatment options. <i>Journal of Bone and Joint Infection</i> , 2018, 3, 212-221.	0.6	8
60	High-level artemisinin-resistance with quinine co-resistance emerges in <i>P. falciparum</i> malaria under in vivo artesunate pressure. <i>BMC Medicine</i> , 2018, 16, 181.	2.3	26
61	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3413-3422.	1.3	40
62	Levetiracetam circulating concentrations and response in status epilepticus. <i>Epilepsy and Behavior</i> , 2018, 88, 61-65.	0.9	13
63	Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania. <i>PLoS ONE</i> , 2018, 13, e0202745.	1.1	1
64	Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 159, 341-347.	1.4	22
65	Appropriateness of malaria diagnosis and treatment for fever episodes according to patient history and anti-malarial blood measurement: a cross-sectional survey from Tanzania. <i>Malaria Journal</i> , 2018, 17, 209.	0.8	9
66	Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An in Vivo Study With an Experimental Model of Foreign-Body Infection. <i>Frontiers in Microbiology</i> , 2018, 9, 919.	1.5	4
67	Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study. <i>HIV Medicine</i> , 2018, 19, 572-577.	1.0	16
68	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
69	Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2540-2545.	1.3	35
70	Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response. <i>Epilepsy Research</i> , 2017, 135, 38-42.	0.8	27
71	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2835-2838.	1.1	15
72	Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2574-2577.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement. <i>Bone and Joint Research</i> , 2017, 6, 296-306.	1.3	58
74	Adequate plasma drug concentrations suggest that amoxicillin can be administered by continuous infusion using elastomeric pumps. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2613-2615.	1.3	18
75	Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1462-1465.	1.3	38
76	Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?. <i>Epilepsy and Behavior</i> , 2017, 74, 41-44.	0.9	11
77	Is gentamicin necessary in the antimicrobial treatment for group B streptococcal infections in the elderly? An in vitro study with human blood products. <i>Infectious Diseases</i> , 2017, 49, 185-192.	1.4	9
78	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	32
79	Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. <i>Frontiers in Microbiology</i> , 2016, 7, 1604.	1.5	23
80	Is Penicillin Plus Gentamicin Synergistic against Clinical Group B Streptococcus isolates?: An In vitro Study. <i>Frontiers in Microbiology</i> , 2016, 7, 1680.	1.5	18
81	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1933-1942.	1.3	13
82	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016, 18, 814-822.	1.1	36
83	Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease. <i>Journal of Hepatology</i> , 2016, 65, 1063-1065.	1.8	7
84	Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. <i>Radiology</i> , 2016, 280, 425-435.	3.6	30
85	The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 5-13.	5.8	29
86	Multigenerational effects of the anticancer drug tamoxifen and its metabolite 4-hydroxy-tamoxifen on <i>Daphnia pulex</i> . <i>Science of the Total Environment</i> , 2016, 545-546, 21-29.	3.9	29
87	An inhibitor of HIV-1 protease modulates constitutive eIF2 $\alpha$ dephosphorylation to trigger a specific integrated stress response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E117-26.	3.3	50
88	Treatment of pleural malignancies by photoinduction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities. <i>Lasers in Surgery and Medicine</i> , 2015, 47, 807-816.	1.1	5
89	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	1.0	5
90	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	1.1	18

#	ARTICLE	IF	CITATIONS
91	Erlotinib. Therapeutic Drug Monitoring, 2015, 37, 2-21.	1.0	36
92	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. Drug Metabolism and Disposition, 2015, 44, 151-161.	1.7	27
93	Pharmacokinetic modelling of dialytic clearance in a case of acyclovir intoxication. International Journal of Antimicrobial Agents, 2015, 45, 325-327.	1.1	2
94	Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Burns, 2015, 41, 956-968.	1.1	47
95	Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report. BMC Gastroenterology, 2015, 15, 38.	0.8	2
96	The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study. Science of the Total Environment, 2015, 520, 232-240.	3.9	24
97	Label-Free Detection of Tobramycin in Serum by Transmission-Localized Surface Plasmon Resonance. Analytical Chemistry, 2015, 87, 5278-5285.	3.2	115
98	Therapeutic drug monitoring of targeted anticancer therapy. Biomarkers in Medicine, 2015, 9, 887-893.	0.6	24
99	Shotgun Ecotoxicoproteomics of <i>Daphnia pulex</i> : Biochemical Effects of the Anticancer Drug Tamoxifen. Journal of Proteome Research, 2015, 14, 279-291.	1.8	16
100	Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemotherapy and Pharmacology, 2014, 74, 1307-1319.	1.1	60
101	Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine, 2014, 6, 372-383.	3.3	311
102	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2014, 69, 2489-2498.	1.3	31
103	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. Journal of Chromatography A, 2014, 1369, 52-63.	1.8	26
104	G.P.105. Neuromuscular Disorders, 2014, 24, 826.	0.3	0
105	Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Analytical and Bioanalytical Chemistry, 2014, 406, 2627-2640.	1.9	34
106	Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania. Antimicrobial Agents and Chemotherapy, 2014, 58, 4583-4592.	1.4	37
107	A simple, robust and rapid approach to detect carbapenemases in Gram-negative isolates by MALDI-TOF mass spectrometry: validation with triple quadrupole tandem mass spectrometry, microarray and PCR. Clinical Microbiology and Infection, 2014, 20, O1106-O1112.	2.8	26
108	Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. Translational Oncology, 2014, 7, 393-399.	1.7	27

#	ARTICLE	IF	CITATIONS
109	Large-scale imatinib doseâ€“concentrationâ€“effect study in CML patients under routine care conditions. <i>Leukemia Research</i> , 2014, 38, 764-772.	0.4	37
110	Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women. <i>Antiviral Therapy</i> , 2013, 18, 171-182.	0.6	31
111	Population pharmacokinetics of mefloquine, piperazine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. <i>Malaria Journal</i> , 2013, 12, 235.	0.8	33
112	The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy. <i>American Journal of Pathology</i> , 2013, 182, 485-504.	1.9	73
113	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1007-1018.	1.1	33
114	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	1.4	22
115	Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and <i>CYP2D6</i> Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 950-958.	1.4	51
116	A validated assay by liquid chromatographyâ€“tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. <i>Journal of Mass Spectrometry</i> , 2013, 48, 616-625.	0.7	45
117	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 28-35.	0.9	86
118	Efavirenz intoxication due to a new CYP2B6 constellation. <i>Antiviral Therapy</i> , 2013, 18, 735-738.	0.6	6
119	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 9-18.	0.7	25
120	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2959-2966.	1.4	39
121	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. <i>Chimia</i> , 2012, 66, 291-295.	0.3	8
122	Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with <i>Aspergillus pneumonia</i> . <i>Aids</i> , 2012, 26, 776-778.	1.0	9
123	Therapeutic Drug Monitoring of Imatinib. <i>Clinical Pharmacokinetics</i> , 2012, 51, 187-201.	1.6	43
124	Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. <i>Lasers in Surgery and Medicine</i> , 2012, 44, 318-324.	1.1	17
125	A highly sensitive LCâ€“tandem MS assay for the measurement in plasma and in urine of salbutamol administered by nebulization during mechanical ventilation in healthy volunteers. <i>Biomedical Chromatography</i> , 2012, 26, 672-680.	0.8	7
126	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2



#	ARTICLE	IF	CITATIONS
127	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	1.1	21
128	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 609-622.	1.5	15
129	Emission wavelength tuning by mechanical stressing of GaAs/Ge/Si microbeams. Optics Express, 2011, 19, 15732.	1.7	7
130	Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncology, The, 2011, 12, 9-11.	5.1	22
131	Determination of Trace Lithium in Human Erythrocytes by Electrothermal Atomic-absorption Spectrometry with Pyrocoated Graphite Tubes and Integrated Platform. Journal of Pharmacy and Pharmacology, 2011, 50, 693-701.	1.2	7
132	Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring. Antiviral Therapy, 2011, 16, 189-197.	0.6	38
133	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood, 2011, 117, e75-e87.	0.6	202
134	Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2011, 27, 525-533.	0.5	8
135	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. Journal of Antimicrobial Chemotherapy, 2011, 66, 1573-1581.	1.3	25
136	Photodynamic Therapy Enhances Liposomal Doxorubicin Distribution in Tumors during Isolated Perfusion of Rodent Lungs. European Surgical Research, 2011, 47, 196-204.	0.6	8
137	Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs. Lasers in Surgery and Medicine, 2010, 42, 391-399.	1.1	19
138	An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: First evidence of 4-hydroxylated metabolites in breast cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3402-3414.	1.2	35
139	Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia. Leukemia Research, 2010, 34, 698-699.	0.4	5
140	Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. BMC Infectious Diseases, 2010, 10, 2.	1.3	21
141	Imatinib plasma levels: correlation with clinical benefit in GIST patients. British Journal of Cancer, 2010, 102, 1198-1199.	2.9	35
142	Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clinical Transplantation, 2010, 24, 794-800.	0.8	14
143	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 2010, 20, 217-230.	0.7	104
144	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. Aids, 2010, 24, 2347-2354.	1.0	101

#	ARTICLE	IF	CITATIONS
145	Residual Antimalarial Concentrations before Treatment in Patients with Malaria from Cambodia: Indication of Drug Pressure. <i>Journal of Infectious Diseases</i> , 2010, 202, 1088-1094.	1.9	19
146	Pharmacokinetics and Pharmacogenomics of Once-Daily Raltegravir and Atazanavir in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4619-4625.	1.4	41
147	Ultra-Performance Liquid Chromatography Mass Spectrometry and Sensitive Bioassay Methods for Quantification of Posaconazole Plasma Concentrations after Oral Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5074-5081.	1.4	21
148	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 464-471.	0.9	17
149	siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. <i>Drug Metabolism Letters</i> , 2010, 4, 114-119.	0.5	24
150	Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. <i>Clinical Pharmacokinetics</i> , 2010, 49, 741-765.	1.6	48
151	Prospective monitoring of cefepime in intensive care unit adult patients. <i>Critical Care</i> , 2010, 14, R51.	2.5	93
152	Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- <i>N</i> -Oxide, Anidulafungin, and Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5303-5315.	1.4	108
153	High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4360-4367.	1.4	147
154	Emission-wavelength control using a mechanically stressed micro-beam structure: GaAs on Si-on-insulator beam. , 2010, , .		0
155	Abstract PD05-09: Prospective Assessment of CYP2D6 by Genotyping, Phenotyping and Measurement of Tamoxifen, 4-Hydroxy-Tamoxifen and Endoxifen in Breast Cancer Patients Treated with Tamoxifen. , 2010, , .		1
156	Residual Antimalarials in Malaria Patients from Tanzania – Implications on Drug Efficacy Assessment and Spread of Parasite Resistance. <i>PLoS ONE</i> , 2009, 4, e8184.	1.1	28
157	Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with <i>Fasciola hepatica</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 543-549.	1.3	22
158	Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3017-3023.	1.4	43
159	Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2009, 8, 635-638.	0.5	14
160	Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1982-1996.	1.2	172
161	A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 331-341.	1.1	5
162	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 485-494.	2.3	113

#	ARTICLE	IF	CITATIONS
163	A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1057-1069.	1.2	101
164	Valganciclovir in Adult Solid Organ Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 399-418.	1.6	65
165	A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 867-886.	1.2	97
166	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 300-309.	0.7	133
167	Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008, 43, 736-752.	0.7	52
168	Distribution of Free and Liposomal Doxorubicin After Isolated Lung Perfusion in a Sarcoma Model. <i>Annals of Thoracic Surgery</i> , 2008, 85, 1225-1232.	0.7	12
169	Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. <i>British Journal of Cancer</i> , 2008, 98, 1633-1640.	2.9	106
170	Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1332-1335.	1.3	18
171	Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 511-522.	1.0	47
172	The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. <i>Aids</i> , 2007, 21, 1309-1315.	1.0	89
173	Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 137-143.	1.4	94
174	Simultaneous alteration of the novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2-Deoxy-(fluoromethylene)cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro. <i>Acta Oncologica</i> , 2007, 46, 612-620.	0.8	8
175	Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 885-890.	0.7	36
176	Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 420-429.	1.2	43
177	Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 557-566.	2.3	240
178	Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. <i>Leukemia</i> , 2007, 21, 1561-1562.	3.3	44
179	Reply to Zong et al.. <i>Leukemia</i> , 2007, 21, 1563-1564.	3.3	2
180	Effect of dronedarone on renal function in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 070727055311005-???	1.1	96

#	ARTICLE	IF	CITATIONS
181	34 Pharmacokinetic and pharmacodynamic evaluation of valganciclovir in solid organ transplant patients. <i>International Journal of Infectious Diseases</i> , 2006, 10, S19.	1.5	0
182	Antegrade Versus Retrograde Isolated Lung Perfusion: Doxorubicin Uptake and Distribution in a Sarcoma Model. <i>Annals of Thoracic Surgery</i> , 2006, 82, 2024-2030.	0.7	10
183	Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. <i>Journal of Hepatology</i> , 2006, 44, 167-175.	1.8	80
184	Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients?. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 332-338.	1.0	19
185	Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 97-112.	1.1	161
186	Orosomucoid ( $\alpha$ 1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 307-318.	2.3	66
187	Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-LIV after solid-phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 832, 138-143.	1.2	15
188	Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial. <i>Clinical Nutrition</i> , 2006, 25, 418-427.	2.3	72
189	Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: Evaluation of different cytotstatic lung perfusion techniques in a porcine model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 304-311.	0.4	14
190	Prospective Determination of Plasma Imipenem Concentrations in Critically Ill Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2563-2568.	1.4	28
191	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3801-3808.	1.4	82
192	Pharmacogenetics in Infectious Diseases. , 2006, , 155-187.		0
193	Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	0.6	6
194	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	0.6	28
195	Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 1-5.	0.7	355
196	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 599-608.	0.7	73
197	Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 259-276.	1.2	100
198	A validated liquid chromatography-mass spectrometry method for the determination of leukotrienes B4 and B5 produced by stimulated human polymorphonuclear leukocytes. <i>Analytical Biochemistry</i> , 2005, 341, 58-68.	1.1	10

#	ARTICLE	IF	CITATIONS
199	Effect of dronedarone on renal function in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, P10-P10.	2.3	3
200	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 865-873.	0.8	70
201	Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia. <i>Dermatology</i> , 2005, 211, 363-365.	0.9	44
202	Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3226-3232.	1.4	36
203	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients. <i>Clinical Cancer Research</i> , 2004, 10, 3728-3736.	3.2	403
204	Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction followed by liquid chromatography-ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 285-292.	1.2	52
205	The bradykinin antagonist icatibant increases electrolyte and water excretion after sodium challenge in patients with liver cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P12.	2.3	1
206	Pharmacokinetic and pharmacodynamic profile of icatibant. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P56.	2.3	2
207	Icatibant has no impact on renal function in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P57.	2.3	0
208	Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2-deoxy-2-(fluoromethylene) cytidine and iododeoxyuridine. <i>European Journal of Cancer</i> , 2004, 40, 1572-1580.	1.3	2
209	Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 810, 25-34.	1.2	19
210	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 20-30.	2.3	231
211	Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. <i>Intensive Care Medicine</i> , 2003, 29, 1844-1848.	3.9	54
212	Population pharmacokinetics and effects of indinavir in HIV infected patients. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, P69-P69.	2.3	2
213	A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 33, 475-494.	1.4	37
214	NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 62-67.	1.1	22
215	Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1329-1340.	1.0	67
216	Functional consequence of MDR1 expression on imatinib intracellular concentrations. <i>Blood</i> , 2003, 102, 1142-1142.	0.6	66

#	ARTICLE	IF	CITATIONS
217	Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. <i>Anticancer Research</i> , 2003, 23, 2757-65.	0.5	18
218	Transplacental passage of protease inhibitors at delivery. <i>Aids</i> , 2002, 16, 889-893.	1.0	102
219	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet</i> , The, 2002, 359, 30-36.	6.3	635
220	Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 127-140.	1.2	44
221	Single-step extraction of fluconazole from plasma by ultra-filtration for the measurement of its free concentration by high performance liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 28, 645-651.	1.4	32
222	Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 29, 17-33.	1.4	25
223	Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Inpatient Variability. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 394-398.	1.0	52
224	Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. <i>Aids</i> , 2001, 15, 71-75.	1.0	743
225	Diet Acids and Alkalis Influence Calcium Retention in Bone. <i>Osteoporosis International</i> , 2001, 12, 493-499.	1.3	205
226	Midazolam premedication reduces propofol dose requirements for multiple anesthetic endpoints. <i>Canadian Journal of Anaesthesia</i> , 2001, 48, 439-445.	0.7	42
227	Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment. <i>Biomedical Applications</i> , 2001, 755, 73-84.	1.7	18
228	Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2001, 24, 391-404.	1.4	43
229	Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2001, 25, 465-475.	1.4	27
230	Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 723-727.	0.8	20
231	'Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients'. <i>Aids</i> , 2001, 15, 1193-1194.	1.0	18
232	Radiation therapy and daily concomitant temozolomide in newly diagnosed glioblastoma multiforme: A safe and promising regimen. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 301.	0.4	0
233	Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. <i>Biomedical Applications</i> , 2000, 740, 43-58.	1.7	99
234	Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. <i>European Journal of Pediatrics</i> , 2000, 159, 919-925.	1.3	57

#	ARTICLE	IF	CITATIONS
235	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , 2000, 14, 1291.	1.0	50
236	Midazolam premedication and thiopental induction of anaesthesia: interactions at multiple end-points. <i>British Journal of Anaesthesia</i> , 1999, 83, 590-595.	1.5	9
237	Trace lithium in mood disorders. <i>Journal of Affective Disorders</i> , 1999, 54, 199-203.	2.0	4
238	Simultaneous Determination of Deoxyribonucleoside in the Presence of Ribonucleoside Triphosphates in Human Carcinoma Cells by High-Performance Liquid Chromatography. <i>Analytical Biochemistry</i> , 1999, 270, 59-68.	1.1	45
239	Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. <i>Annals of Oncology</i> , 1999, 10, 831-838.	0.6	41
240	Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100 240, on endocrine and renal functions in healthy volunteers. <i>Journal of Hypertension</i> , 1999, 17, 427-437.	0.3	30
241	Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 433-440.	1.1	62
242	Estimation of Glomerular Filtration Rate by Sinistrin Clearance Using Various Approaches. <i>Renal Failure</i> , 1998, 20, 267-276.	0.8	9
243	Specific Determination of PAH and Its N-Acetyl Metabolite by HPLC Increases the Accuracy and Precision of PAH Clearance Measurements. <i>Renal Failure</i> , 1998, 20, 311-317.	0.8	2
244	Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. <i>Journal of Hypertension</i> , 1998, 16, 385-393.	0.3	69
245	Sinistrin Clearance for Determination of Glomerular Filtration Rate: A Reappraisal of Various Approaches Using a New Analytical Method. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 679-692.	1.0	33
246	Spectrophotometric determination of methylene blue in biological fluids after ion-pair extraction and evidence of its adsorption on plastic polymers. <i>European Journal of Pharmaceutical Sciences</i> , 1997, 5, 335-345.	1.9	21
247	High-performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements. <i>Biomedical Applications</i> , 1997, 703, 25-36.	1.7	16
248	Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: Variability of urine matrices circumvented by cation exchange solid phase extraction. <i>Pharmaceutica Acta Helveticae</i> , 1996, 71, 237-246.	1.2	37
249	Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1996, 14, 483-490.	1.4	17
250	Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. <i>Biomedical Applications</i> , 1995, 667, 291-300.	1.7	47
251	The differential cytotoxicity of cardenolides from <i>Thevetia peruviana</i> . <i>Phytotherapy Research</i> , 1994, 8, 74-77.	2.8	17
252	Novel Naphthoquinones from <i>Conospermum incurvum</i> . <i>Journal of Natural Products</i> , 1994, 57, 1511-1516.	1.5	25

#	ARTICLE	IF	CITATIONS
253	HIV inhibitory natural products. 11. Structure, absolute stereochemistry, and synthesis of conocurvone, a potent, novel HIV-inhibitory naphthoquinone trimer from a <i>Conospermum</i> sp. <i>Journal of the American Chemical Society</i> , 1993, 115, 6673-6679.	6.6	74
254	Isolation, Structure and Synthesis of Conocurvone, a Potent, Novel HIV-Inhibitory Naphthoquinone Trimer from <i>Conospermum</i> Species. <i>Planta Medica</i> , 1993, 59, A581-A581.	0.7	2
255	A New Phloroglucinol Derivative from <i>Hypericum calycinum</i> with Antifungal and in vitro Antimalarial Activity 1. <i>Planta Medica</i> , 1991, 57, 548-551.	0.7	60
256	Centrifugal Partition Chromatography: A Recently Developed Liquid-Liquid Technique for the Rapid Isolation of Natural Products. <i>Planta Medica</i> , 1990, 56, 498-498.	0.7	0
257	New Constituents with Growth-Inhibitory Activity against the Co-115 Human Colon Carcinoma Cell Line and A New Antifungal Phloroglucinol Derivative from <i>Hypericum calycinum</i> . <i>Planta Medica</i> , 1989, 55, 629-630.	0.7	2
258	New Hyperforin Derivatives from <i>Hypericum revolutum</i> VAHL with Growth-Inhibitory Activity against a Human Colon Carcinoma Cell Line. <i>Helvetica Chimica Acta</i> , 1989, 72, 464-471.	1.0	36
259	Isolation of New Cytotoxic Constituents from <i>Hypericum revolutum</i> and <i>Hypericum calycinum</i> by Liquid-Liquid Chromatography. <i>Planta Medica</i> , 1988, 54, 560-560.	0.7	4
260	New Antifungal Chromenyl Ketones and their Pentacyclic Dimers from <i>Hypericum revolutum</i> VAHL. <i>Helvetica Chimica Acta</i> , 1987, 70, 1694-1702.	1.0	38
261	Application of semi-preparative high-performance liquid chromatography to difficult natural product separations. <i>Journal of Chromatography A</i> , 1987, 406, 367-373.	1.8	14
262	Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPLA™ HIV Trial). <i>Frontiers in Virology</i> , 0, 2, .	0.7	0
263	Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response. <i>European Journal of Neurology</i> , 0, , .	1.7	4
264	Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	0